JCRB0435 JHH-4

細胞情報

Important Notice(s)

On the agreement for distribution of JHH series cell lines, NOZ and OZ

細胞種類:一般細胞 (細胞分譲手数料はこちら)

細胞番号(JCRB)   JCRB0435 細胞名   JHH-4
生物種(日本語)   ヒト 組織名(日本語)   肝臓, 胆嚢
コメント(日本語)   肝細胞がん プロフィール   Human hepatocellular carcinoma cell line.
別名    動物名   human
系統名    学名・属名   Homo
種名   sapiens 性別   M
年齢・月齢   51 細胞識別情報   available
(癌)原発組織名   liver, gallbladder 病歴情報   hepatocellular carcinoma
転移の有無(Y/N)    (癌)転移組織名   
遺伝的性質   HBV integration is not observed. 細胞寿命   infinite
クライシスPDL    形態   epithelial-like
一般性状   Alpha-phetoprotein and albumin-producing cell line. HBs antigen-negative. HCV was not detected by an RT-PCR method tested in the HSRRB. 細胞分類   tumor
細胞樹立者名   Hasumura,S. et al. 細胞寄託者   Nagamori,S.
分譲時制限   Require negotiation and agreement from Dr.Nagamori before shipping. コメント   Cell Bank will handle to get the approval but the depositor may contact to the requested person directly.
入手年   1988 培養培地   Eagle's minimal essential medium with 10% fetal calf serum.
継代方法   Cells are harvested after the treatment with 0.25% trypsin and 0.02% EDTA at room temp. for 5 min. 継代時細胞数   1-2x10^4 cells/sq.cm.
人種   Japanese 炭酸ガス濃度   5 %
採取組織名   liver ウィルス検査   tested
検出ウィルス   CMV(-), EBV(-), HHV6(-), HHV7(-), BKV(-), JCV(-), ADV(-), parvoB19(-), HBV(-), HTLV1(-), HTLV2(-), HIV1(-), HIV2(-), HPV18(-) [-/negative, +/positive] 組織型   
Link
COSMIC CELL LINE COSMIC(Catalogue Of Somatic Mutations In Cancer)は、ヒトのがんで検出された体細胞変異のオンラインデータベースです。 特にCell Lines Projectでは、1000以上の細胞株の変異プロファイルが登録されています。 JCRB細胞バンクに登録されている細胞株については、右のリンクから情報を得ることができます。 1240158
Reference
Pubmed id:2856444

. 0;():


Research results by users. Click!
Pubmed id:29087505 Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
Mak A,Kato R,Weston K,Hayes A,Uetrecht J
Toxicol Sci. 2018 Feb 1;161(2):412-420
Pubmed id:28081667 Contributions of caspase-8 and -9 to liver injury from CYP2E1-produced metabolites of halogenated hydrocarbons.
Ijiri Y,Kato R,Sadamatsu M,Takano M,Yasuda Y,Tanaka F,Oishi C,Imano H,Okada Y,Tanaka K,Hayashi T
Xenobiotica. 2018 Jan;48(1):60-72
Pubmed id:28525267 Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes.
Kato R,Uetrecht J
Chem Res Toxicol. 2017 Jun 19;30(6):1327-1332
Pubmed id:27183710 Effect of hypoxia on UDP-glucuronosyl transferase mRNA expression in human hepatocarcinoma functional liver celL4 cell line.
Kato R,Matsura A,Kamiya R,Oishi C,Kagawa Y,Tanaka F,Matsumoto N,Ijiri Y,Hayashi T
Pharmazie. 2016 Mar;71(3):152-3
Pubmed id:24599999 Novel permissive cell lines for complete propagation of hepatitis C virus.
Shiokawa M,Fukuhara T,Ono C,Yamamoto S,Okamoto T,Watanabe N,Wakita T,Matsuura Y
J Virol. 2014 May;88(10):5578-94
Pubmed id:20044606 Infrequent amplification of JUN in hepatocellular carcinoma.
Endo M,Yasui K,Nakajima T,Gen Y,Tsuji K,Dohi O,Zen K,Mitsuyoshi H,Minami M,Itoh Y,Taniwaki M,Tanaka S,Arii S,Okanoue T,Yoshikawa T
Anticancer Res. 2009 Dec;29(12):4989-94
Pubmed id:18248513 Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
Takahata T,Ookawa K,Suto K,Tanaka M,Yano H,Nakashima O,Kojiro M,Tamura Y,Tateishi T,Sakata Y,Fukuda S
Basic Clin Pharmacol Toxicol. 2008 Apr;102(4):399-407
Pubmed id:17549407 Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues.
Kondoh N,Imazeki N,Arai M,Hada A,Hatsuse K,Matsuo H,Matsubara O,Ohkura S,Yamamoto M
Int J Oncol. 2007 Jul;31(1):81-7
Pubmed id:16522372 A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines.
Murata M,Nabeshima S,Kikuchi K,Yamaji K,Furusyo N,Hayashi J
Cytokine. 2006 Feb 7;33(3):121-8
Pubmed id:16041541 Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment.
Yamaji K,Nabeshima S,Murata M,Chong Y,Furusyo N,Ikematsu H,Hayashi J
Cancer Immunol Immunother. 2006 Apr;55(4):394-403
Pubmed id:15349899 Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells.
Yokoo H,Kondo T,Fujii K,Yamada T,Todo S,Hirohashi S
Hepatology. 2004 Sep;40(3):609-17
Pubmed id:10766424 Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation.
Murakami K,Matsuura T,Hasumura S,Nagamori S,Yamada Y,Saiki I
Cancer Lett. 2000 Apr 3;151(1):63-70
Pubmed id:9446792 Cyclin E overexpression responsible for growth of human hepatic tumors with p21WAF1/CIP1/SDI1.
Tsuji T,Miyazaki M,Fushimi K,Mihara K,Inoue Y,Ohashi R,Ohtsubo M,Hamazaki K,Furusako S,Namba M
Biochem Biophys Res Commun. 1998 Jan 14;242(2):317-21
Pubmed id:8835345 Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
Tsuboi S,Nagamori S,Miyazaki M,Mihara K,Fukaya K,Teruya K,Kosaka T,Tsuji T,Namba M
J Med Virol. 1996 Feb;48(2):133-40
Pubmed id:1315167 Induction of allogeneic tumour- and lymphokine-activated lymphocytes against hepatocellular carcinoma.
Yasumura S,Higuchi K,Hioki O,Okada K,Tsukishiro T,Tsuchida T,Miyagiwa M,Nambu S,Yasuyama T,Inoue K
J Gastroenterol Hepatol. 1992 Mar-Apr;7(2):136-41
Pubmed id:1651985 Preferential expression of the large hepatitis B virus surface antigen gene by an adenovirus-hepatitis B virus recombinant.
Yuasa T,Kajino K,Saito I,Miyamura T
J Gen Virol. 1991 Aug;72 ( Pt 8)():1927-34
Pubmed id:1701409 Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines.
Fujise K,Nagamori S,Hasumura S,Homma S,Sujino H,Matsuura T,Shimizu K,Niiya M,Kameda H,Fujita K
Hepatogastroenterology. 1990 Oct;37(5):457-60
Pubmed id:2543327 [Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro].
Hasumura S,Nagamori S,Fujise K,Homma S,Sujino H,Matsuura T,Shimizu K,Niiya M,Kameda H
Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 2-3):1905-12
Pubmed id:2856444 [Establishment and characterization of a human hepatocellular carcinoma cell line JHH-4].
Hasumura S,Sujino H,Nagamori S,Kameda H
Hum Cell. 1988 Mar;1(1):98-100
Pubmed id:2856500 [Effects of TNF on human hepatocellular carcinoma cell lines and their modification by hyperthermia].
Hasumura S,Nagamori S,Fujise K,Homma S,Sujino H,Matsuura T,Shimizu K,Niiya M,Kameda H,Satomi N
Hum Cell. 1988 Jun;1(2):238-44
Pubmed id:3428672 An epidemic of pseudomembranous colitis: importance of person to person spread.
Nolan NP,Kelly CP,Humphreys JF,Cooney C,O'Connor R,Walsh TN,Weir DG,O'Briain DS
Gut. 1987 Nov;28(11):1467-73
Pubmed id:none THE MORPHOLOGICAL STUDY OF HUMAN CULTURED HEPATOMA CELLS BY A NEW PLASMA POLYMERIZATION REPLICA METHOD AND TEM
Hajime SUJINO
Jikeikai Medical Journal 33(4), 379-400 (1986)
Pubmed id:none ヒト肝癌細胞株に対するTumor necrosis factorの影響
蓮村哲 永森静志 藤瀬清隆 本間定 筋野甫 松浦知和 清水恵一郎 新谷稔 里見信子
医学のあゆみ 143(8), 655-656 (1987)
Pubmed id:none Fluorochromeを用いたchromatin DNAのcolorimetric assay法による単層培養細胞増殖動態の検討
松浦知和 永森静志 藤瀬清隆 蓮村哲 本間定 筋野甫 清水恵一郎 新谷稔 亀田治男
医学のあゆみ 142(13), 957-958 (1987)
Pubmed id:none 樹立ヒト肝癌株細胞中のB型肝炎ウイルスゲノム
藤瀬 清隆, 藤多 和信, 永森 静志, 蓮村 哲, 本間 定, 筋野 甫, 松浦 知和, 清水 恵一郎, 新谷 稔, 大野 典也, 亀田 治男
肝臓 29(5), 697-698 (1988)

Images
Movies



LOT Information

細胞番号   JCRB0435 細胞名   
培養ロット番号   04142005 培養種別   distribution
培地   Eagle's minimal essential medium with 10% fetal bovine serum (FBS lot; GIBCO 4218333S) 培養温度   37 C
継代時細胞数(濃度)   5 - 15 x 10^4 cells/ml 継代方法   0.25% trypsin and 0.02% EDTA at room temperature for 5 min.
増殖速度   approx. 40.5 hrs 凍結時生細胞濃度   2.3 x 10^6
凍結直後生細胞率   97.1 使用抗生物質   free
継代数   P17 PDL数(プライマリ)   
マイコプラズマ検出   - 細菌汚染検出   -
真菌汚染検出   - アイソザイム検査・動物名   Confirmed as human by NP, G6PD (type B), MD.
染色体モード    染色体情報   
表面抗原    DNA Profile (STR)   
接着性   Yes 導入外部遺伝子   
凍結培地   10% DMSO, 20% FBS - Eagle's MEM 炭酸ガス濃度   5%
RFPL所見    追加情報   
細胞番号   JCRB0435 細胞名   JHH-4
培養ロット番号   061897 培養種別   distribution
培地   Eagle's minimal essential medium with 10% fetal calf serum (Mitsubishi PVF01). 培養温度   37 C
継代時細胞数(濃度)   1-2x10^6 cells/sq.cm. 継代方法   Cells are harvested after the treatment with 0.25% trypsin and 0.02% EDTA at room temp. for 5 min.
増殖速度   NT 凍結時生細胞濃度   3.0x10^6
凍結直後生細胞率   92.0 使用抗生物質   free
継代数   P13 PDL数(プライマリ)   NT
マイコプラズマ検出   - 細菌汚染検出   -
真菌汚染検出   - アイソザイム検査・動物名   NT
染色体モード   NT 染色体情報   NT
表面抗原   NT DNA Profile (STR)   
接着性   Yes 導入外部遺伝子   NT
凍結培地   Culture mdium with 5% DMSO. 炭酸ガス濃度   
RFPL所見    追加情報   
Images
細胞番号   JCRB0435 細胞名   JHH-4
培養ロット番号   04142014 培養種別   distribution
培地   Eagle's minimal essential medium with 10% fetal calf serum (FBS; GIBCO Cat. # 10091). 培養温度   37 C
継代時細胞数(濃度)   4.7 - 9.0 x 10^4 cells/mL 継代方法   Cells were harvested after the treatment with 0.25% trypsin and 0.02% EDTA.
増殖速度    凍結時生細胞濃度   2.9 x 10^6
凍結直後生細胞率   96.0 使用抗生物質   free
継代数   P17 PDL数(プライマリ)   
マイコプラズマ検出   - 細菌汚染検出   -
真菌汚染検出   - アイソザイム検査・動物名   
染色体モード    染色体情報   
表面抗原    DNA Profile (STR)   D5S818:9,13
D13S317:12
D7S820:10,12
D16S539:12,13
VWA:14,17
TH01:6,9
AM:X
TPOX:8,11
CSF1PO:11,12
接着性   Yes 導入外部遺伝子   
凍結培地   10% DMSO, 20% FBS - EMEM 炭酸ガス濃度   5%
RFPL所見    追加情報   Cell Bank will handle to get the approval but the depositor may contact to the requester directly.
CLOSE